Revvity Inc.
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Revvity Inc. (RVTY). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Life Sciences [Member] | – | – | $1.29B 39.0% | $1.46B 53.0% · +12.8% | $1.40B 50.8% · -4.1% | $1.43B 50.1% · +2.3% |
| Diagnostics [Member] | – | – | $2.02B 61.0% | $1.29B 47.0% · -36.0% | $1.36B 49.2% · +5.0% | $1.42B 49.9% · +5.1% |
| Discovery & Analytical Solutions [Member] | $596.3M 22.4% | – | – | – | – | – |
| Diagnostics [Member] | $2.07B 77.6% | $2.93B 76.6% · +41.8% | – | – | – | – |
| Life Sciences [Member] | – | $895.9M 23.4% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Product [Member] | $2.28B 85.6% | $2.74B 71.5% · +19.9% | $2.63B 79.6% · -3.7% | $2.42B 87.8% · -8.3% | $2.34B 84.9% · -3.2% | $2.39B 83.7% · +2.2% |
| Service [Member] | $382.4M 14.4% | $1.09B 28.5% · +185.8% | $677.2M 20.4% · -38.0% | $334.7M 12.2% · -50.6% | $416.8M 15.1% · +24.5% | $466.1M 16.3% · +11.8% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.